companydata.dkcompanydata.dk

ZEALAND PHARMA A/S: Financial statements 2022

CVR: 20045078

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

ZEALAND PHARMA A/S (CVR 20045078) has filed annual accounts for 2022. In 2022, the company reported revenue of EUR 103,986,000 and a net result of EUR -1,202,135,000 compared with DKK -1,018,149,000 the year before. That is a decrease of 64.5% compared with the year before. The profit margin was -1,156.1%. Equity in the 2022 report amounted to EUR 815,911,000. The solvency ratio was 53%. The company had 247 employees in the financial year.

Revenue
EUR 103,986,000
Gross Profit
EUR 103,986,000
Profit/Loss
EUR -1,202,135,000
Equity
EUR 815,911,000
Total Assets
EUR 1,539,806,000
Employees
247

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022104M EUR104M EUR-1.2B EUR815.9M EUR247
2021292.6M173.8M-1B927.8M346
2020353.3M262.7M-846.7M1.2B297
201941.3M--571.5M1.2B-
201838M-581.3M1.1B-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on ZEALAND PHARMA A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

ZEALAND PHARMA A/S publishes interim reportNov 23, 2022

ZEALAND PHARMA A/S has published its interim report for the period January 1, 2022 to September 30, 2022.

Henriette Wennicke joins ZEALAND PHARMA A/S as directorNov 1, 2022

As of November 1, 2022, Henriette Wennicke is registered as director of ZEALAND PHARMA A/S.

Matthew Donald Dallas steps down as director of ZEALAND PHARMA A/SAug 31, 2022

As of August 31, 2022, Matthew Donald Dallas has stepped down as director of ZEALAND PHARMA A/S.

ZEALAND PHARMA A/S publishes interim reportAug 29, 2022

ZEALAND PHARMA A/S has published its interim report for the period January 1, 2022 to March 31, 2022.

ZEALAND PHARMA A/S publishes interim reportAug 29, 2022

ZEALAND PHARMA A/S has published its interim report for the period January 1, 2022 to June 30, 2022.

ZEALAND PHARMA A/S: The 2021 annual report is outMay 4, 2022

ZEALAND PHARMA A/S has published its annual report for 2021. Revenue came to DKK 292,567,000, and the net result was DKK -1,018,149,000.

Adam Sinding Steensberg joins ZEALAND PHARMA A/S as adm. dir.Mar 30, 2022

As of March 30, 2022, Adam Sinding Steensberg is registered as adm. dir. of ZEALAND PHARMA A/S.

Emmanuel Dulac steps down as adm. dir. of ZEALAND PHARMA A/SMar 30, 2022

As of March 30, 2022, Emmanuel Dulac has stepped down as adm. dir. of ZEALAND PHARMA A/S.

Adam Sinding Steensberg steps down as director of ZEALAND PHARMA A/SMar 29, 2022

As of March 29, 2022, Adam Sinding Steensberg has stepped down as director of ZEALAND PHARMA A/S.

About ZEALAND PHARMA A/S

ZEALAND PHARMA A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1997. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ZEALAND PHARMACEUTICALS A/S and PEPTIDE PROBE TECHNOLOGIES ApS. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The board consists of Alf Gunnar Martin Nicklasson (chair), Kirsten Aarup Drejer, Adam Krisko Nygaard and Anneline Nansen. The company's owners include ZEALAND PHARMA A/S, Van Herk Investments B.V. and Van Herk Management Services B.V.. The company has 575 employees (2026). In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. Equity in the 2025 report amounted to DKK 14,830,613,000.

Source: annual report 2025, Danish Business Authority